-
Gilenya Remains Favorite S1P Receptor Modulator in US, But Zeposia May Catch Up, Survey Says
Spherix Global Insights surveyed physicians about S1P receptor modulators Zeposia, Gilenya and Mayzent for multiple sclerosis. Click here to find out what they said.
Did anything stand out to you about the physicians’ feedback?
Sorry, there were no replies found.
Log in to reply.